2Leong BK,Sabatiis CP,Rop DA,et al. Alterations in the cardiopulmonary effects and pharmacokinetics of a bisphosphonate drug bya cytoehrome P2450 inhibitor in conscious rats[J]. J Appl Toxicol,1997,17(5):279- 288
3Abbas R, Hayton WL. A physiologically based pharmacokinetic andpharmacodynamic model for paraoxon in rainbow trot[J]. Toxicol Appl Pharmacol, 1997,145(3) : 192 - 201
4McCain WC, Flaherty DM, Correll L, et al. Catecholaraine concentrations and contractile responses of isolated vessel from henstreated with cyclic phenyl saligenin phosphate of paraoxon in the presenceor absence of verapamil[ J ]. J Toxicol Environ Health, 1996,48 (7):397-411
5Brown MA,Brix KA. Review of heath consequences from high intermediate and low level exposure to oranophosphosphorus nerve agents[J]. J Appl Toxicol, 1998,18(7) :393 - 408
